| Jul 15 |
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
|
| Jul 11 |
Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%
|
| Jul 9 |
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
|
| Jul 8 |
Lexicon appoints Mike Exton as CEO, Jeff Wade as COO
|
| Jul 8 |
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
|
| Jun 21 |
Sector Update: Health Care Stocks Gain in Late Afternoon
|
| Jun 21 |
Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes
|
| Jun 21 |
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
|
| Jun 19 |
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
|
| Jun 18 |
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
|
